2.39%
-14.14%
25.08%
29.14%
7.16%
128.62%
110.05%
AI Spotlight on NAMS
Company Description
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases.Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C).The company was founded in 2019 and is based in Naarden, the Netherlands.
Market Data
| Last Price | 22.29 |
| Change Percentage | 2.39% |
| Open | 21.72 |
| Previous Close | 21.77 |
| Market Cap ( Millions) | 2381 |
| Volume | 1289408 |
| Year High | 27.29 |
| Year Low | 15.19 |
| M A 50 | 23.42 |
| M A 200 | 19.89 |
Financial Ratios
| FCF Yield | -6.16% |
| Dividend Yield | 0.00% |
| ROE | -53.79% |
| Debt / Equity | 0.13% |
| Net Debt / EBIDTA | 245.81% |
| Price To Book | 5.57 |
| Price Earnings Ratio | -11.57 |
| Price To FCF | -16.23 |
| Price To sales | 69.77 |
| EV / EBITDA | -11.41 |
News
- Jan -09 - NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Dec -13 - NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares
- Dec -12 - NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
- Dec -11 - NewAmsterdam Pharma: Positive Obicetrapib Data Leads To New Catalysts
- Dec -10 - NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
- Dec -10 - Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday?
- Dec -10 - NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia
- Dec -06 - NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Nov -20 - NewAmsterdam Dives — And Sacrifices A Cup Base — Despite A Winning Cholesterol Study
- Nov -18 - NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024
- Nov -01 - NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Oct -28 - NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November
- Oct -04 - NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Oct -04 - Obicetrapib Positions NewAmsterdam Pharma For Significant Market Growth In Cardiovascular Therapies
- Sep -06 - NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Aug -30 - NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September
- Aug -28 - NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside
- Aug -02 - NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Jul -29 - NewAmsterdam Touts Cholesterol Drug Success, But Results Trail Analysts' Expectations
- Jul -26 - NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Transformative Therapies for Cardio-metabolic Diseases
Expected Growth : 10.43 %
What the company do ?
Transformative Therapies from NewAmsterdam Pharma Company N.V. are novel treatments targeting cardio-metabolic diseases, focusing on improving insulin sensitivity and reducing cardiovascular risk.
Why we expect these perspectives ?
NewAmsterdam Pharma's transformative therapies for cardio-metabolic diseases are driven by increasing prevalence of obesity and diabetes, growing demand for innovative treatments, and strong clinical trial results. The company's focus on precision medicine, gene therapy, and RNA-based approaches also contributes to its growth, as well as strategic partnerships and expanding pipeline.
Newamsterdam Pharma Company N.V. Products
| Product Range | What is it ? |
|---|---|
| Obicetrapib | Obicetrapib is an oral, small molecule inhibitor of cholesterol ester transfer protein (CETP), a protein that facilitates the transfer of cholesterol from HDL to LDL and VLDL, thereby reducing HDL levels. |
| KAF156 | KAF156 is an oral, small molecule inhibitor of PCSK9, a protein that regulates LDL receptor degradation, thereby reducing LDL levels. |
| NAP802 | NAP802 is an oral, small molecule inhibitor of the apolipoprotein C-III (apoC-III) protein, which is involved in triglyceride metabolism. |
NewAmsterdam Pharma Company N.V.'s Porter Forces
Threat Of Substitutes
NewAmsterdam Pharma Company N.V. operates in a highly competitive industry, and there are many substitutes available in the market. However, the company's strong brand recognition and customer loyalty mitigate the threat of substitutes to some extent.
Bargaining Power Of Customers
NewAmsterdam Pharma Company N.V. has a large customer base, but the bargaining power of customers is high due to the availability of alternative products and services. The company needs to focus on customer retention and loyalty programs to reduce the bargaining power of customers.
Bargaining Power Of Suppliers
NewAmsterdam Pharma Company N.V. has a diversified supplier base, and the bargaining power of suppliers is low. The company has a strong negotiating position, which enables it to secure favorable prices and terms from its suppliers.
Threat Of New Entrants
The pharmaceutical industry has high barriers to entry, including regulatory hurdles and high research and development costs. However, NewAmsterdam Pharma Company N.V. needs to continuously innovate and invest in research and development to stay ahead of potential new entrants.
Intensity Of Rivalry
The pharmaceutical industry is highly competitive, and NewAmsterdam Pharma Company N.V. faces intense rivalry from established players. The company needs to focus on differentiating its products and services to gain a competitive advantage.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 0.02% |
| Debt Cost | 3.95% |
| Equity Weight | 99.98% |
| Equity Cost | 4.35% |
| WACC | 4.35% |
| Leverage | 0.02% |
NewAmsterdam Pharma Company N.V. : Quality Control
NewAmsterdam Pharma Company N.V. passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| PHM.MC | Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest … |
| LVTX | LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the … |
| CALTX.ST | Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It … |
| PRQR | ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III … |
| CNTA | Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Pharma Mar
A-Score
1-Year Total Return ->
🥈
Calliditas Therapeutics
A-Score
1-Year Total Return ->
🥉
ProQR Therapeutics
A-Score
1-Year Total Return ->
4
Centessa Pharmaceuticals
A-Score
1-Year Total Return ->
5
LAVA Therapeutics
A-Score
1-Year Total Return ->
6
